Premium Nahrungsergänzungsmittel | artgerecht

JAK Inhibitor: Mechanism, Uses & Side Effects

JAK inhibitors are medications that selectively block Janus kinases, used to treat inflammatory and autoimmune conditions.

Regular tips about health Regular tips about health

Things worth knowing about "JAK inhibitor"

JAK inhibitors are medications that selectively block Janus kinases, used to treat inflammatory and autoimmune conditions.

What Is a JAK Inhibitor?

A JAK inhibitor (also known as a Janus kinase inhibitor or JAKi) is a type of medication that selectively blocks enzymes called Janus kinases (JAK). These enzymes play a key role in transmitting inflammatory signals inside cells. By inhibiting this signaling pathway, JAK inhibitors help control the overactive immune responses seen in autoimmune and inflammatory diseases.

Mechanism of Action

Janus kinases are intracellular enzymes linked to the JAK-STAT signaling pathway. When cytokines (such as interleukins or interferons) bind to cell surface receptors, they activate JAK enzymes, which in turn phosphorylate STAT proteins (Signal Transducers and Activators of Transcription). These proteins then travel to the cell nucleus and regulate the expression of genes involved in inflammation and immune responses.

JAK inhibitors disrupt this process by blocking JAK enzyme activity. There are four known Janus kinases: JAK1, JAK2, JAK3, and TYK2. Depending on the selectivity of a given JAK inhibitor, one or more of these enzymes may be targeted.

Indications (Approved Uses)

JAK inhibitors are used to treat a range of inflammatory and autoimmune conditions, including:

Rheumatoid arthritis
Psoriatic arthritis
Ankylosing spondylitis
Atopic dermatitis (eczema)
Ulcerative colitis and Crohn's disease
Alopecia areata (patchy hair loss)
Myelofibrosis and other hematologic disorders

Known JAK Inhibitors

Approved JAK inhibitors include:

Tofacitinib (Xeljanz) – JAK1/JAK3 inhibitor
Baricitinib (Olumiant) – JAK1/JAK2 inhibitor
Upadacitinib (Rinvoq) – selective JAK1 inhibitor
Ruxolitinib (Jakafi/Jakavi) – JAK1/JAK2 inhibitor, used in myelofibrosis
Filgotinib (Jyseleca) – selective JAK1 inhibitor

Dosage and Administration

JAK inhibitors are typically taken as oral tablets or capsules, which is a key advantage over biologic therapies that usually require injection or infusion. Some JAK inhibitors are also available as topical formulations (e.g., creams for skin conditions). The appropriate dosage depends on the indication, the specific drug, and the individual patient profile, and must always be prescribed by a physician.

Side Effects

As with all immunomodulating medications, JAK inhibitors can cause side effects, including:

Increased risk of infections (e.g., herpes zoster, upper respiratory infections)
Blood count changes (decreased red or white blood cell counts)
Elevated blood lipid levels (hyperlipidemia)
Liver enzyme abnormalities
In rare cases: increased risk of thromboembolic events (blood clots) and cardiovascular events
Possible increased risk of malignancy in certain patient groups

Regular monitoring and follow-up appointments are required during treatment with JAK inhibitors.

Contraindications and Precautions

JAK inhibitors should be used with caution or avoided in the following situations:

Active infections (particularly tuberculosis)
Severe renal or hepatic impairment
Pregnancy and breastfeeding
Elevated cardiovascular risk or history of thrombosis
Patients over 65 years of age (increased risk profile)

JAK Inhibitors Versus Biologics

Compared to biologic therapies (e.g., TNF blockers), JAK inhibitors offer the advantage of oral administration and potentially faster onset of action. Biologics are highly specific monoclonal antibodies that target individual cytokines or receptors, while JAK inhibitors act on a broader intracellular signaling pathway. The choice between these treatment options depends on the specific disease, the patient's risk profile, and their response to prior therapies.

References

Schwartz DM, Kanno Y, Villarino A, et al. - JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature Reviews Drug Discovery, 2017.
European Medicines Agency (EMA) - Product information for approved JAK inhibitors (baricitinib, tofacitinib, upadacitinib, ruxolitinib). https://www.ema.europa.eu
Smolen JS, Landewé RBM, et al. - EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2023.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.